March 2025, Vol 6, No 1

The ACCORD trial demonstrated that adjuvant chemoradiation combined with immunotherapy significantly improved survival outcomes in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer compared with observation alone.

A study of patients with advanced biliary tract cancer found that adding lenvatinib to durvalumab and gemcitabine-based chemotherapy improved progression-free survival, objective response rate, and disease control rate.

A study of patients with advanced biliary tract cancer found that HER2 positivity is associated with poorer prognosis but that HER2-targeted therapies can improve outcomes.

The 2025 ASCO GI Cancers Symposium on biliary tract cancer (BTC) emphasized significant research findings, particularly the relevance of mutational subsets, the role of personalized medicine, and the impact of multidisciplinary therapies on enhancing outcomes for patients with BTC.

The Cholangiocarcinoma Foundation is providing a video series for patients and caregivers. Patients can access informational videos through electronic health records.

In a real-world study, MDM2-amplified, TP53 wild-type disease does not appear to be a prognostic biomarker for survival.

A dose optimization study found that zanidatamab 20 mg/kg every 2 weeks is the optimal dose for patients with HER2-positive biliary tract cancer.

A real-world study demonstrated how comprehensive genomic profiling can guide treatment decisions for metastatic biliary tract cancer, suggesting the addition of immunotherapy to standard chemotherapy may worsen outcomes for patients with specific mutations.

A study using a next-generation sequencing biorepository identified specific genomic alterations that predict response and resistance to targeted therapy in biliary tract cancer patients.

A phase 2 clinical trial of tinengotinib in patients with advanced cholangiocarcinoma showed promising antitumor efficacy.

Clinical trial recruitment and retention remain challenging in bringing innovative medicines to patients. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups.